Unichem Labs diabetes drug Sitagliptin gets USFDA approval
Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Mumbai: Unichem Laboratories Limited has recently announced that the company has received tentative approval for Abbreviated New Drug Application (ANDA) of Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg from the United States Food and Drug Administration (USFDA).The product is a generic version of Januvia (sitagliptin) tablets, 25 mg, 50 mg, and 100 mg, of Merck Sharpe and...
Mumbai: Unichem Laboratories Limited has recently announced that the company has received tentative approval for Abbreviated New Drug Application (ANDA) of Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg from the United States Food and Drug Administration (USFDA).
The product is a generic version of Januvia (sitagliptin) tablets, 25 mg, 50 mg, and 100 mg, of Merck Sharpe and Dohme Corp (Merck).
Read also: Unichem Labs gets USFDA nod for Amitriptyline HCl Tablets
Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Product will be commercialized from Unichem's Goa Plant on receipt of full approval.
Read also: Unichem Labs secures USFDA nod for Aripiprazole Tablets
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd